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Objectives: To determine if the starting time of chemotherapy influences on ill-
ness-free survival and general survival in a cohort of Mexican patients with breast 
cancer. MethOds: A prospective study over 5 years was performed on 88 women 
with breast cancer from the National Medical Centre “La Raza” of the Mexican 
Institute of Social Security (IMSS) with the following characteristics: stages I-III and 
positive criteria for adjuvant chemotherapy. The time range for the chemotherapy 
administration was 0 to 2, 3 and > 4 months. The analysis was performed regarding 
chemotherapy administration time interval using a Kaplan-Meier estimator. The 
Cox model was adjusted to see the relationships between the global survival and the 
oestrogen and progesterone hormone receptor variables and HER2/NEU as well as 
their basal characteristics. Results: For both IFS and GS there was a significantly 
statistical difference on the survival distributions related to starting time of chemo-
therapy which had a higher probability from a range of 0 to 2 months (median GS 
59 months median IFS 49 months; p-value< 0.001). Regarding general survival, the 
hormonal receptors for oestrogen, progesterone and HER2/NEU do not influence 
on the Cox model (p-value= 0.137, 0.823, 0.524 respectively); for the Cox model with 
basal characteristics, age, pathological state and time interval between surgery and 
chemotherapy influenced significantly on GS (p-value< 0.05) cOnclusiOns: The 
probability of survival for IFS and GS improve when chemotherapy is administered 
within the first 2 months after surgery. Also, there was a greater risk for GS when 
time interval between surgery and chemotherapy was prolonged. This delay for the 
starting time of chemotherapy will impact without a doubt in the health systems´ 
economy, generating more expenses for attention.
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Objectives: To investigate treatment and survival patterns among ALK+ non-
small cell lung cancer (NSCLC) patients following discontinuation with crizotinib 
monotherapy. MethOds: Medical charts for ALK+ NSCLC patients who discon-
tinued treatment with crizotinib monotherapy were retrospectively reviewed and 
abstracted by a panel of 27 oncologists. Patients were randomly selected by phy-
sicians among their eligible crizotinib-treated patients. Results: A total of 119 
ALK+NSCLC patients who received crizotinib monotherapy and changed regimen 
prior to death or last follow-up were analyzed. At primary NSCLC diagnosis, patients 
averaged 65 years old and 56% (n= 66) were male. A majority of them received first-
line crizotinib monotherapy (60% first-line; 33% second-line), and median crizotinib 
treatment duration for all 119 patients was 141 days (IQR: 92-209). Before chang-
ing crizotinib monotherapy regimen, 38 (32%) patients were diagnosed with brain 
metastases. A total of 102 (86%) patients had progressed while on crizotinib mono-
therapy after a median time of 140 days (IQR: 88-219) post crizotinib initiation, and 
changed regimen after a median of 1 day (IQR: 1-3) post progression. After discon-
tinuing crizotinib, 50 (42%) patients did not receive antineoplastic therapy. Among 
the 69 patients (58%) who received treatment, 37 (54%) received chemotherapy, 15 
(22%) radiation therapy without chemotherapy, 13 (19%) a targeted therapy, and 
4 (6%) were enrolled in a clinical trial. Among all patients, median survival post 
crizotinib monotherapy was 61 days. The median survival was 180 days for the 69 
patients who received treatment post crizotinib monotherapy and 17 days for those 
who did not receive antineoplastic therapy. The median survival was 44 days for 
the 38 patients with brain metastases. cOnclusiOns: There is significant unmet 
need among patients progressing on crizotinib. In this retrospective study, ALK+ 
NSCLC patients were found to have an overall survival of 61 days post crizotinib 
monotherapy; additional studies are necessary to understand clinical outcomes 
among patients progressing on crizotinib.
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Objectives: Lung cancer is the leading cause of cancer related death in Canada. 
Lobectomy is the most common form of treatment for early stage lung cancer and 
can be performed using an open approach with a thoracotomy incision or as a 
minimally-invasive procedure using Video-Assisted Thoracic Surgery (VATS). Several 
recent studies have demonstrated that open and VATS lobectomies achieve onoco-
logically equivalent outcomes, which has lead to rising popularity for VATS. In the 
Canadian health care environment hospitals are faced with increasingly restrictive 
budgets, creating a critical need to demonstrate the cost-effectiveness of procedures 
performed. This study was conducted to determine the budget impact of increasing 
the proportion of VATS vs. open lobectomies in a Canadian hospital. MethOds: 
We examined the budget impact of increasing the proportion of VATS cases from 
25% to 75%, while decreasing the proportion of open cases by the same amount 
in a hospital that performs 150 lobectomies annually. The model incorporates the 
costs associated with surgery, length of stay (taking into account facility and staff 
costs) and common postoperative complications. The cost data used in the model 
was obtained from peer reviewed literature, the Ontario Case Costing Initiative and 
case costing from a large Canadian hospital. Data on patient outcomes was obtained 
risk of the therapeutic class overall. MethOds: A population-based case control 
study was conducted using HealthCore Integrated Research Database (HIRDSM), a 
US commercial insurance claims database. Incident cases of CC were defined as 
patients, ≥ 18 years at diagnosis, with 1st CC diagnostic claim between Jan 1, 2001 to 
Jan 30, 2011. Each case was matched to 1 eligible control based on: no diagnosis of CC 
during study period, actively enrolled at index date of the case, matched to cases by 
length of pre-index enrollment (same or greater), gender & age. Exposure to CV drug 
was defined as at least 1 claim during risk period. Conditional logistic regression was 
used to calculate adjusted Odds Ratios (OR). Sensitivity analysis was conducted where 
minimum CV drug exposure (12 months) was required. Results: 36,736 cases of CC 
were identified in the HIRDSM& successfully matched to controls. Mean age was 60 
years (about 30% were 50-60 years old).Enalapril, labetalol, cholestyramin, diltiazem 
& furosemide (ORs range:1.07-2.05) were positively associated with CC while atorvas-
tatin, pravastatin & simvastatin (ORs range:0.68-0.94) were negatively associated with 
CC. In the sensitivity analyses, positive associations remained for cholestyramine 
& diltiazem, whereas negative associations remained for atorvastatin & simvasta-
tin. cOnclusiOns: These results are consistent with a beneficial impact of statins 
on CC risk. Prolonged use of a small number of CV agents was associated with CC. 
Cholestyramine & diltiazem are associated with increased risk of CC because of the 
condition for which they are prescribed. However, association of individual drugs was 
not consistent with that therapeutic class as a whole. This suggests that cancer risk 
is sometimes drug specific. Grouping drugs into therapeutic classes for studies of 
cancer risk may introduce a bias such that the predominant drug drives the results.
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Objectives: The U.S. Food and Drug Administration issued a statement indicating 
that pioglitazone, one of the type II diabetes oral hypoglycemic agents, may poten-
tially increase the risk of developing bladder cancer in 2010. This study examined the 
relationship between pioglitazone and incidence rate of bladder cancer among type 
2 diabetes patients in Taiwan by population-based data without financial support 
from any institution. MethOds: We analyzed 8 years cohort (2003-2010) in Taiwan 
by using National Health Insurance Database. Approximately 2 million randomly 
sampled representative beneficiaries from the National Health Insurance database 
were used as the data source for analysis. Totally 4,765 patients used pioglitazone 
were followed and compared with 4,765 control cases selected by propensity score 
matched approach. Results: We found that risk of bladder cancer increases with 
age, and risk increased higher for men than women, with a hazard ratio of 1.8. With 
propensity score matching, no significant correlation was found between the risk 
of bladder cancer and pioglitazone using. There was no significant difference in 
survival curves between patients ever used and never used pioglitazone. There is a 
tendency of getting bladder cancer earlier for patients ever used compared to never 
users yet it is not statistically significant. cOnclusiOns: A significant increase 
risk of bladder cancer is observed for patients ever used compared to all diabetes 
patients who never used pioglitazone; however, the risk diminishes after adjust-
ing with propensity score matching. Our study results indicated that the potential 
hazard of pioglitazone might be overestimated.
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Objectives: While most patients with advanced stages of melanoma generally 
have a poor prognosis, some patients gain long-term benefit from cancer therapy 
and therefore significantly surpass the expected survival time. The goal of the 
study was to investigate whether long-term survivors of advanced melanoma have 
excess mortality risk compared to the general population. MethOds: Data per-
taining to 783 patients diagnosed with stage IIIC or IV melanoma during 2003-2011 
were derived from The Netherlands Cancer Registry. The mean age at diagnosis 
was 60.5 years for patients with stage IIIC (n= 414) and 62.1 years with stage IV 
disease (n= 369). Monthly survival rates were derived from the estimated Kaplan-
Meier survival curves for each subgroup for up to 9.6 years of follow-up. Smoothed 
hazard rates were derived from the survival curves. Analysis was conducted to 
determine whether after 5 years of follow-up the 95% confidence interval (CI) of the 
smoothed hazard observed for advanced melanoma patients included that observed 
for a comparable group from the Dutch general population. Results: Median sur-
vival was estimated to be 1.93 years (95%-CI 1.69-2.11) and 0.52 years (0.45-0.62) in 
patients with stage IIIC and IV, respectively. The Kaplan-Meier estimates indicated 
survival rates of 71%, 48%, 33%, 25%, and 21% for stage IIIC and 30%, 20%, 14%, 
10%, and 8% for stage IV melanoma at 1, 2, 3, 5, and 9.6 years respectively. After 
5 years of follow-up the ranges indicated by the 95% CIs of the empirical hazard 
profiles contained that of the general population; the confidence interval ranges 
were small. cOnclusiOns: Relative to the general population, no excess risk was 
found in advanced melanoma patients who survived 5 years and beyond. These 
findings suggest that long-term survival extrapolation approaches should be tested 
for face-validity with general population mortality data.
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ALK-positive, advanced NSCLC in Argentina. MethOds: A budget impact model 
we developed to evaluate two separate scenarios from a payer’s perspective. The 
model compared scenarios with and without crizotinib. In the crizotinib scenario all 
patients testing positive for the ALK mutation were given crizotinib. Comparators 
were platin-containing regimens (ex pemetrexed), platin/pemetrexed, erlotinib/gefi-
tinib, and crizotinib. Epidemiology, market basket, adverse event costs, and drug 
costs were informed through ten local physician questionnaires and published 
literature. The survey was administered to oncologists in six different private and 
public hospitals of varying sizes and locations in Argentina. Costs are in 2013 USD 
(1 USD = 5.88 ARS). Results: Considering the population of Argentina (42,610,981) 
and applying age based incidence rates, the number of lung cancer patients was 
estimated to be 12,139. Of those patients 82.5% were estimated to be have metastatic 
NSCLC and 74% were likely to be treated, leaving 7,411 treated patients in the model. 
The estimated one-year cost for treating these patients without crizotinib was esti-
mated to be $205,874,409. In the scenario including crizotinib, 154 patients (market 
uptake of 2.08%) were taken from other regimens and given crizotinib resulting in an 
estimated one-year cost of $224,651,145. The incremental total cost between these 
scenarios was $18,776,736 while the incremental costs per ALK+ patient and per 
member were $211 and $.04 respectively. These results were robust under standard 
parameter estimate variations. cOnclusiOns: Adding crizotinib as a treatment 
option may have an acceptable budget impact under standard practices.
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Objectives: In Brazil, health insurance companies (HIC) must, according to the law, 
offer coverage for intravenous (IVChem) antineoplastic drugs. The obligation to pay 
for oral drugs (OChem) was effective only after January 2014. Our goal was to evaluate 
the incremental costs and budgetary impact of the incorporation of OChem, using 
real world data, from the private payers’ perspective. MethOds: During one year (Jun 
2012-mai 2013) we prospectively collected data on chemotherapy usage in 25 HIC, with 
a population of 3 million people from different regions in Brazil. First we calculated 
the costs of IVChem actually used. After that, we identified which patients would have 
formal indication for OChem either as a substitutive treatment or in association with 
IVChem. Then, we calculated the costs associated with this intervention. Later, the 
budgetary impact of using OChem for the eligible patients was calculated. Only drug 
acquisition costs were taken into account. We analyzed two scenarios: one with a 
total substitution of IVChem for OChem, when OChen treatment was less expensive 
than IVChem and another, using a “worst case scenario” approach, were OChem 
was used only in cases where it added costs. Results: During the one-year period, 
2,104 patients that received intravenous chemotherapy also had formal indication to 
receive OChem. If OChem had been used, in a rational protocol-based manner, there 
would have been an economy of R$ 0,10 (US$ 0,42) per HIC user per month. In the 
worst-case scenario, the incremental cost would be an additional R$ 0,39 (US$ 0,16) 
per HIC user per month. cOnclusiOns: The budgetary impact secondary to OChem 
adoption may vary from decreasing costs to increasing them; depending on how they 
are used and to which patient they are prescribed. HIC should pay close attention to 
the profile of use of OChem in order to avoid unnecessary costs.
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Objectives: In a Phase III clinical trial (Von Hoff, NEJM 2013) albumin-bound 
paclitaxel (nab-P) plus gemcitabine (nab-P/G) significantly improved median over-
all survival (OS) in first-line metastatic pancreatic cancer (1LmPanc) patients vs. 
gemcitabine (G) alone (8.7 vs. 6.6 months, hazard ratio 0.72, P< 0.001). The objective 
of this analysis is to estimate the budget impact of adding nab-P/G for 1LmPanc 
treatment at a US health plan. MethOds: A budget impact model was built to 
estimate 1LmPanc costs for nab-P/G, G, Erlotinib + Gemcitabine (EG), Other G com-
binations (OG), and FOLFIRINOX (F), from a US health plan perspective in 2013 US 
dollars. Inputs for drug, administration, G-CSF, and adverse events were derived 
from prescribing information, publications, Medicare reimbursement rates, and 
other public sources. Sensitivity analysis assessed utilization mixes and elderly 
populations. Results: A 1,000,000-member health plan mirroring the US popula-
tion age mix would have 70 patients with 1LmPanc annually. The model assumed 
equal proportions of G, EG, OG, and F (25% of patients each) at baseline, and equal 
use (20% each) after nab-P/G 1LmPanc approval. Total course of therapy costs were 
G $2,634, EG $22,555, OG $10,840, F $39,437. Baseline total mPanc costs were $1.3 
million, or $0.11 per member per month (PMPM). Adding nab-P/G at $29,096 per 
course of therapy added $142,610, or $0.01 PMPM, to the baseline. In a sensitivity 
analysis with 50% of patients using nab-P/G, incremental cost was $0.03 PMPM. For 
a health plan population age 65-79, baseline cost of $0.48 PMPM rose $0.05 PMPM 
from nab-P/G. If only 70% of 1LmPanc patients received drug therapy, costs from nab-
P/G rose $0.01 from $0.08 PMPM at baseline. cOnclusiOns: The budget impact of 
adding albumin-bound paclitaxel plus gemcitabine for a US health plan’s first-line 
metastatic pancreatic cancer patients was estimated at $0.01 PMPM; the impact 
was consistent across several sensitivity analyses.
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from peer reviewed literature. A multivariate sensitivity analysis using a Monte Carlo 
simulation was completed to ensure scientific rigour. Results: VATS lobectomies 
are associated with higher procedural costs, but this is offset by a shorter length of 
stay and a lower postoperative complication rate. The model establishes that for a 
Canadian hospital performing 150 lobectomies increasing the proportion of VATS 
cases from 25% to 75% allows for a potential cost savings of CAD $226,066.01 annu-
ally. cOnclusiOns: In a Canadian hospital, VATS lobectomy is a more cost-effective 
procedure than open lobectomy for early stage lung cancer.
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Objectives: Radium-223, an intravenously injected radioactive agent, is a new 
therapeutic option for CRPC patients with symptomatic bone metastases and no 
known visceral metastatic disease. This budget impact model (BIM) was developed 
from a United States (US) payer perspective to estimate the economic impact of 
adding radium-223 to current treatment options in this population. MethOds: An 
Excel-based BIM evaluated costs of treating CRPC with symptomatic bone metas-
tases and no known visceral metastatic disease with available treatment options 
(chemotherapies, radionuclides, and oral antiandrogens) in a health plan with and 
without radium-223. One-year incremental costs were estimated for a hypothetical 
health plan with 1 million members. The prevalence of metastatic CRPC (mCRPC) 
patients was obtained from the national registry and published literature. Cost of 
therapy was obtained from Medicare average sales prices (ASP). Assumptions of out-
patient administration and laboratory utilization were derived from product-specific 
package inserts with costs transformed into costs per 4 weeks based on indicated 
dosing. Associated costs were derived from the Centers for Medicare & Medicaid 
Services (CMS) Physician Fee Schedule. Results: An estimated 220 patients were 
eligible for treatment with radium-223. Radium-223 was assumed to adopt 6.4% of 
the market in year 1 with equiproportional pull from available treatment options; 
a cost of $11,500 per 28-day cycle was assumed. In this base-case scenario, costs 
rose 1.7% ($208,755) or $0.02 per member per month (PMPM) compared to a health 
plan without radium-223. Sensitivity analyses, varying default inputs ± 10%, showed 
that results were robust, with greatest sensitivity to the number of radium-223 
doses ($0.01–$0.03 PMPM). Other key variables such as cycles of treatment, num-
ber of patients treated, and market share resulted in no change to PMPM budget 
impact. cOnclusiOns: Economic modeling indicates that adding radium-223 to a 
health plan’s formulary minimally increases the PMPM cost by $0.02.
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Objectives: Life Technologies has developed a 14-gene molecular assay (PervenioTM 
Lung RS) that provides mortality risk stratification in resected early-stage non-
squamous NSCLC. The test classifies patients as low, intermediate, or high-risk 
(for death), informing decisions about adjuvant chemotherapy use. Accordingly, 
high-risk patients may benefit from chemotherapy, and low-risk patients can avoid 
chemotherapy-associated morbidity and costs. Our objective was to estimate the 
budget impact of covering the assay in hypothetical commercial and Medicare 
health plans. MethOds: We developed a Markov model to estimate costs before 
and after coverage of the 14-gene RS in commercial (age < 65) and Medicare (age 
65+) health plans with 1 million enrollees. Health plan age distributions and disease 
incidence were derived from the U.S. census and SEER, respectively. Risk-group 
classification was based on 14-gene RS clinical studies, and chemotherapy uptake 
was based on a study of pre/post testing recommendations from 58 surgeons/
oncologists. Included costs were those of the assay, chemotherapy with NCCN-
recommended regimens, monitoring, post-recurrence care, and adverse events. We 
calculated the total and per-member per-month (PMPM) 1-year budget impact of 
adding coverage for the 14-gene RS, and evaluated uncertainty using one-way sensi-
tivity analyses. Results: The 1-year budget impact of covering the 14-gene RS assay 
in commercial and Medicare health plans with 1 million members is expected to be 
$24,200 (PMPM= $0.002) and $178,800 (PMPM= $0.015), respectively. The most influen-
tial parameters were the proportion of high-risk patients receiving chemotherapy, 
the chemotherapy recurrence hazard ratio, and the proportion of patients receiving 
initial surgical treatment. cOnclusiOns: Our analysis suggests that covering the 
14-gene RS assay is expected to increase chemotherapy use, decrease recurrences, 
and result in a small net increase in PMPM cost in commercial and Medicare health 
plans. These outcomes indicate that the assay has the potential to provide positive 
health outcomes for health plan members at a reasonable cost.
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Objectives: Non-small cell lung cancer (NSCLC) accounts for the majority of lung 
cancer cases and a high number of these patients have metastatic cancer at the time 
of diagnosis. The ALK mutation is only found in about 4% of NSCLC patients. The 
study aims to evaluate the budgetary impact of adding crizotinib for patients with 
